Skip to content

Haemoadsorption During Heart Transplantation

Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05270902
Acronym
CytoSorbHTX
Enrollment
40
Registered
2022-03-08
Start date
2022-09-01
Completion date
2026-06-30
Last updated
2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplantation

Keywords

Heart Transplantation, Cytosorb

Brief summary

To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated

Interventions

Polymer based adsorber system for the elimination of cytokines

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Prospective, single-center, single-blinded, randomized, controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients undergoing heart transplantation

Exclusion criteria

* Declined informed consent * Age \< 18 years# * Receiving antileukocyte drugs * Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab) * DCD * Ex-vivo perfusion

Design outcomes

Primary

MeasureTime frameDescription
Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)5 daysDifference in maximal cytokine peak levels in various cytokine levels compared to baseline measured by ELISA

Secondary

MeasureTime frameDescription
Difference of immunosuppression (sST2)30daysIndividual immunosuppression measured by sST2 levels
primary graft dysfunction score7 daysDifferences in primary graft dysfunction score between both groups
Difference of immunosuppression (TTV)30daysIndividual immunosuppression measured by Torque-teno-virus load
Mechanical Ventilationup to 4 weeksDifferences in length of mechanical ventilation
Delirium5 daysDifferences in Confusion assessment method for the ICU between both groups
30-day mortality30 daysDifferences in 30-day mortality between both groups

Countries

Austria

Contacts

Primary ContactMartin H. Bernardi, MD, PhD
martin.bernardi@meduniwien.ac.at0043140400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026